{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:49:20Z","timestamp":1788306560049,"version":"build-2803163510"},"reference-count":36,"publisher":"American Academy of Pediatrics (AAP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,9,1]]},"abstract":"<jats:sec>\n                  <jats:title>BACKGROUND:<\/jats:title>\n                  <jats:p>The capsular group B meningococcal vaccine (4CMenB) is recommended for children with complement deficiencies, asplenia, and splenic dysfunction; however, data on the immunogenicity of 4CMenB in these \u201cat-risk\u201d children are missing.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS:<\/jats:title>\n                  <jats:p>Participants aged 2 to 17 years in Italy, Spain, Poland, the United Kingdom, and Russia with complement deficiencies, asplenia, or splenic dysfunction received 2 doses of 4CMenB 2 months apart, as did healthy children in the control group. Exogenous and endogenous human complement serum bactericidal activity (SBA) was determined at baseline and 1 month after the second immunization against 4 test strains: H44\/76 (assessing vaccine antigen factor H binding protein), 5\/99 (Neisserial adhesion A), NZ98\/254 (Porin A), and M10713 (Neisserial heparin binding antigen).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS:<\/jats:title>\n                  <jats:p>Of 239 participants (mean age 10.3 years, 45% female), 40 children were complement deficient (9 eculizumab therapy, 4 terminal-chain deficiencies, 27 \u201cother\u201d), 112 children had asplenia or splenic dysfunction (8 congenital asplenia, 8 functional asplenia, 96 splenectomy), and 87 children were in the control group. After immunization, the proportions of complement-deficient participants with exogenous complement SBA titers \u22651:5 were 87% (H44\/76), 95% (5\/99), 68% (NZ98\/254), and 73% (M10713), compared with 97%, 100%, 86%, and 94%, respectively, for asplenic children and 98%, 99%, 83%, and 99% for children in the control group. When testing with endogenous complement, strain-specific bactericidal activity was evident in only 1 eculizumab-treated participant and 1 terminal chain complement-deficient participant.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS:<\/jats:title>\n                  <jats:p>4CMenB administration is similarly immunogenic in healthy children and those with asplenia or splenic dysfunction. The significance of the trend to lower responses of SBA titers in complement-deficient children (especially those with terminal chain complement deficiency or those on eculizumab therapy) must be determined by ongoing surveillance for vaccine failures.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1542\/peds.2017-4250","type":"journal-article","created":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T07:25:22Z","timestamp":1533108322000},"source":"Crossref","is-referenced-by-count":25,"title":["Meningococcal B Vaccine Immunogenicity in Children With Defects in Complement and Splenic Function"],"prefix":"10.1542","volume":"142","author":[{"given":"Federico","family":"Martin\u00f3n-Torres","sequence":"first","affiliation":[{"name":"Translational Pediatrics and Infectious Diseases, Hospital Clinico Universitario de Santiago de Compostela, Santiago de Compostela, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Bernatowska","sequence":"additional","affiliation":[{"name":"Department of Immunology, The Children\u2019s Memorial Health Institute, Warsaw, Poland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Shcherbina","sequence":"additional","affiliation":[{"name":"Research and Clinical Centre of Pediatric Hematology, Oncology and Immunology named after Dmitry Rogachev, Moscow, Russian Federation;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Esposito","sequence":"additional","affiliation":[{"name":"Pediatric Clinic, Department of Surgical and Biomedical Sciences, Universit\u00e0 degli Studi di Perugia, Perugia, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leszek","family":"Szenborn","sequence":"additional","affiliation":[{"name":"Department of Pediatric Infectious Diseases, Wroclaw Medical University, Wroclaw, Poland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magda Campins","family":"Marti","sequence":"additional","affiliation":[{"name":"Hospital Universitario Vall d\u2019Hebron, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Hughes","sequence":"additional","affiliation":[{"name":"Royal Manchester Children\u2019s Hospital, Manchester, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saul N.","family":"Faust","sequence":"additional","affiliation":[{"name":"National Institute for Health Research Wellcome Trust Clinical Research Facility, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis I.","family":"Gonzalez-Granado","sequence":"additional","affiliation":[{"name":"Immunodeficiencies Unit, Department of Pediatrics, University Hospital 12 de Octubre, Research Institute Hospital 12 Octubre (i+12) and Associate Professor of Pediatrics, Complutense University of Madrid, Madrid, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ly-Mee","family":"Yu","sequence":"additional","affiliation":[{"name":"Nuffield Department of Primary Care Health Sciences and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"D\u2019Agostino","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Amsterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Calabresi","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Siena, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Toneatto","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Siena, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Snape","sequence":"additional","affiliation":[{"name":"Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom;"},{"name":"National Institute for Health Research Oxford Biomedical Research Centre, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2018,9,1]]},"reference":[{"key":"2021120916240548000_B1","author":"Committee for Medicinal Products for Human Use. European Medicines Agency."},{"key":"2021120916240548000_B2","unstructured":"Australian Register of Therapeutic Goods\n          . ARTG ID 190719 - BEXSERO. 2013. Available at: http:\/\/search.tga.gov.au\/s\/search.html?collection=tga-artg&profile=record&meta_i=190719. Accessed June 25, 2016"},{"key":"2021120916240548000_B3","unstructured":"US Food and Drug Administration\n          . BEXSERO. 2015. Available at: https:\/\/www.fda.gov\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/ucm431374.htm. Accessed June 25, 2016"},{"issue":"3","key":"2021120916240548000_B4","first-page":"E140","article-title":"Meningococcal B vaccine and the vision of a meningitis free world.","volume":"56","author":"Bianchi","year":"2015","journal-title":"J Prev Med Hyg"},{"key":"2021120916240548000_B5","unstructured":"Canadian Paediatric Society\n          . Update on invasive meningococcal vaccination for Canadian children and youth. Available at: https:\/\/www.cps.ca\/en\/documents\/position\/invasive-meningococcal-vaccination. Accessed April 4, 2018"},{"key":"2021120916240548000_B6","unstructured":"JCVI\n          . JCVI position statement on use of Bexsero meningococcal vaccine in the UK. 2014. Available at: https:\/\/www.gov.uk\/government\/publications\/meningococcal-b-vaccine-jcvi-position-statement. Accessed June 25, 2016"},{"key":"2021120916240548000_B7","unstructured":"National Immunisation Advisory Committee\n          . Immunisation guidelines for Ireland chapter 13 Meningococcal infection. 2016. Available at: www.hse.ie\/eng\/health\/immunisation\/hcpinfo\/guidelines\/chapter13.pdf. Accessed June 25, 2016"},{"issue":"3","key":"2021120916240548000_B8","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1155\/2015\/732464","article-title":"Parents\u2019 and adolescents\u2019 willingness to be vaccinated against serogroup B meningococcal disease during a mass vaccination in Saguenay-Lac-St-Jean (Quebec).","volume":"26","author":"Dub\u00e9","year":"2015","journal-title":"Can J Infect Dis Med Microbiol"},{"issue":"3","key":"2021120916240548000_B9","first-page":"E125","article-title":"Meningococcal serogroup B vaccine in Italy: state-of-art, organizational aspects and perspectives.","volume":"56","author":"Signorelli","year":"2015","journal-title":"J Prev Med Hyg"},{"key":"2021120916240548000_B10","unstructured":"Public Health England\n          . Immunisation against infectious disesase. Chapter 7, immunisation of individuals with underlying medical conditions. 2014. Available at: www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/309218\/Green_Book_Chapter_7_v1_3.pdf. Accessed June 25, 2016"},{"issue":"11\u201312","key":"2021120916240548000_B11","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1007\/s00103-015-2253-z","article-title":"Background paper for the update of meningococcal vaccination recommendations in Germany: use of the serogroup B vaccine in persons at increased risk for meningococcal disease.","volume":"58","author":"Hellenbrand","year":"2015","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"key":"2021120916240548000_B12","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/j.jinf.2016.04.017","article-title":"Immunisation of the immunocompromised child.","volume":"72","author":"Pinto","year":"2016","journal-title":"J Infect"},{"key":"2021120916240548000_B13","unstructured":"Center for Disease Control and Prevention\n          . Meningococcal vaccination: what everyone should know. 2017. Available at: https:\/\/www.cdc.gov\/vaccines\/vpd\/mening\/public\/index.html. Accessed April 4, 2018"},{"issue":"3","key":"2021120916240548000_B14","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/BF02918259","article-title":"Complement deficiency states and meningococcal disease.","volume":"12","author":"Figueroa","year":"1993","journal-title":"Immunol Res"},{"issue":"1","key":"2021120916240548000_B15","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/bjh.12347","article-title":"Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria.","volume":"162","author":"Hillmen","year":"2013","journal-title":"Br J Haematol"},{"issue":"9","key":"2021120916240548000_B16","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1002\/bjs.1800780904","article-title":"Postsplenectomy sepsis and its mortality rate: actual versus perceived risks.","volume":"78","author":"Holdsworth","year":"1991","journal-title":"Br J Surg"},{"issue":"10","key":"2021120916240548000_B17","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1001\/jama.1981.03320100055033","article-title":"Fulminant Meningococcemia after splenectomy.","volume":"246","author":"Holmes","year":"1981","journal-title":"JAMA"},{"issue":"27\u201330","key":"2021120916240548000_B18","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1016\/S0264-410X(03)00440-7","article-title":"Long term effects of vaccination of patients deficient in a late complement component with a tetravalent meningococcal polysaccharide vaccine.","volume":"21","author":"Platonov","year":"2003","journal-title":"Vaccine"},{"issue":"6","key":"2021120916240548000_B19","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1001\/jama.2012.85","article-title":"Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial.","volume":"307","author":"Gossger","year":"2012","journal-title":"JAMA"},{"issue":"6","key":"2021120916240548000_B20","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/j.1365-3083.1993.tb01677.x","article-title":"Antibody response to meningococcal polysaccharides A and C in patients with complement defects.","volume":"37","author":"Biselli","year":"1993","journal-title":"Scand J Immunol"},{"issue":"4","key":"2021120916240548000_B21","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1159\/000070219","article-title":"Antibody-dependent killing of meningococci by human neutrophils in serum of late complement component-deficient patients.","volume":"130","author":"Platonov","year":"2003","journal-title":"Int Arch Allergy Immunol"},{"issue":"6","key":"2021120916240548000_B22","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1128\/CVI.00007-09","article-title":"Ex vivo model of meningococcal bacteremia using human blood for measuring vaccine-induced serum passive protective activity.","volume":"16","author":"Plested","year":"2009","journal-title":"Clin Vaccine Immunol"},{"issue":"7","key":"2021120916240548000_B23","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1182\/blood-2017-05-781450","article-title":"Eculizumab treatment and impaired opsonophagocytic killing of meningococci by whole blood from immunized adults.","volume":"130","author":"Konar","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2021120916240548000_B24","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1128\/IAI.72.1.332-337.2004","article-title":"Immune response to meningococcal serogroup C conjugate vaccine in asplenic individuals.","volume":"72","author":"Balmer","year":"2004","journal-title":"Infect Immun"},{"issue":"7","key":"2021120916240548000_B25","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/INF.0000000000000327","article-title":"Persistence of bactericidal antibodies to 5 years of age after immunization with serogroup B meningococcal vaccines at 6, 8, 12 and 40 months of age.","volume":"33","author":"McQuaid","year":"2014","journal-title":"Pediatr Infect Dis J"},{"issue":"7","key":"2021120916240548000_B26","doi-asserted-by":"crossref","first-page":"E215","DOI":"10.1503\/cmaj.141200","article-title":"Persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 months.","volume":"187","author":"McQuaid","year":"2015","journal-title":"CMAJ"},{"issue":"9816","key":"2021120916240548000_B27","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0140-6736(11)61713-3","article-title":"Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b\/3 randomised, observer-blind, placebo-controlled study.","volume":"379","author":"Santolaya","year":"2012","journal-title":"Lancet"},{"issue":"3","key":"2021120916240548000_B28","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.eimc.2016.02.015","article-title":"Meningococcemia in vaccinated patient under treatment with eculizumab.","volume":"35","author":"Hernando Real","year":"2017","journal-title":"Enferm Infecc Microbiol Clin"},{"issue":"3","key":"2021120916240548000_B29","doi-asserted-by":"crossref","first-page":"e20162452","DOI":"10.1542\/peds.2016-2452","article-title":"Meningococcal B vaccine failure with a penicillin-resistant strain in a young adult on long-term Eculizumab.","volume":"140","author":"Parikh","year":"2017","journal-title":"Pediatrics"},{"issue":"9","key":"2021120916240548000_B30","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1111\/ajt.14426","article-title":"High risk for invasive Meningococcal disease among patients receiving Eculizumab (Soliris) despite receipt of Meningococcal vaccine.","volume":"17","author":"McNamara","year":"2017","journal-title":"Am J Transplant"},{"issue":"6","key":"2021120916240548000_B31","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2014-3503","article-title":"Case report: benefits and challenges of long-term eculizumab in atypical hemolytic uremic syndrome.","volume":"135","author":"Cullinan","year":"2015","journal-title":"Pediatrics"},{"issue":"3","key":"2021120916240548000_B32","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/ajt.12032","article-title":"Meningococcal sepsis complicating eculizumab treatment despite prior vaccination.","volume":"13","author":"Struijk","year":"2013","journal-title":"Am J Transplant"},{"issue":"2","key":"2021120916240548000_B33","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.molimm.2014.06.030","article-title":"Are complement deficiencies really rare? Overview on prevalence, clinical importance and modern diagnostic approach.","volume":"61","author":"Grumach","year":"2014","journal-title":"Mol Immunol"},{"issue":"1","key":"2021120916240548000_B34","doi-asserted-by":"crossref","first-page":"30","DOI":"10.7326\/0003-4819-160-1-201401070-00731","article-title":"Elevated risk for invasive meningococcal disease among persons with HIV.","volume":"160","author":"Miller","year":"2014","journal-title":"Ann Intern Med"},{"key":"2021120916240548000_B35","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1186\/s12916-015-0538-6","article-title":"Risk of invasive meningococcal disease in children and adults with HIV in England: a population-based cohort study.","volume":"13","author":"Simmons","year":"2015","journal-title":"BMC Med"},{"issue":"4","key":"2021120916240548000_B36","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1097\/INF.0000000000001056","article-title":"Persistence of bactericidal antibodies after infant serogroup B Meningococcal immunization and booster dose response at 12, 18 or 24 months of age.","volume":"35","author":"Snape","year":"2016","journal-title":"Pediatr Infect Dis J"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2017-4250\/1064910\/peds_20174250.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2017-4250\/1064910\/peds_20174250.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T04:36:49Z","timestamp":1639111009000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/142\/3\/e20174250\/38569\/Meningococcal-B-Vaccine-Immunogenicity-in-Children"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,1]]},"references-count":36,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,9,1]]},"published-print":{"date-parts":[[2018,9,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2017-4250","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,1]]},"article-number":"e20174250"}}